High-dose etoposide in treatment of metastatic breast cancer

W. R. Bezwoda; L. Seymour; S. Ariad

doi:10.1159/000227021

High-dose etoposide in treatment of metastatic breast cancer

W. R. Bezwoda
, L. Seymour
, S. Ariad

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

High-dose etoposide (1500-2500 mg/m²) was used for the treatment of 23 previously treated patients with advanced breast cancer. Six of 23 (26%) showed objective regression with a median duration of response of 5 months. Responses were seen at all sites apart from bone. Response was related to dose level with 11/23 responses of measurable lesions occurring at doses ≥2000 mg/m² as compared to 2/23 responses at a dose of 1500 mg/m². The treatment regimen was able to be given on an outpatient basis with only routine supportive measures. High-dose etoposide may come to play a role in high-dose combination chemotherapy regimens for advanced breast cancer.

Original language	English
Pages (from-to)	104-107
Number of pages	4
Journal	Oncology
Volume	49
Issue number	2
DOIs	https://doi.org/10.1159/000227021
State	Published - 1 Jan 1992
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Breast cancer
Etoposide
High-dose chemotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1159/000227021

Cite this

@article{154cfeb5496542af98cbefabfe46a087,

title = "High-dose etoposide in treatment of metastatic breast cancer",

abstract = "High-dose etoposide (1500-2500 mg/m2) was used for the treatment of 23 previously treated patients with advanced breast cancer. Six of 23 (26\%) showed objective regression with a median duration of response of 5 months. Responses were seen at all sites apart from bone. Response was related to dose level with 11/23 responses of measurable lesions occurring at doses ≥2000 mg/m2 as compared to 2/23 responses at a dose of 1500 mg/m2. The treatment regimen was able to be given on an outpatient basis with only routine supportive measures. High-dose etoposide may come to play a role in high-dose combination chemotherapy regimens for advanced breast cancer.",

keywords = "Breast cancer, Etoposide, High-dose chemotherapy",

author = "Bezwoda, \{W. R.\} and L. Seymour and S. Ariad",

year = "1992",

month = jan,

day = "1",

doi = "10.1159/000227021",

language = "English",

volume = "49",

pages = "104--107",

journal = "Oncology",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - High-dose etoposide in treatment of metastatic breast cancer

AU - Bezwoda, W. R.

AU - Seymour, L.

AU - Ariad, S.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - High-dose etoposide (1500-2500 mg/m2) was used for the treatment of 23 previously treated patients with advanced breast cancer. Six of 23 (26%) showed objective regression with a median duration of response of 5 months. Responses were seen at all sites apart from bone. Response was related to dose level with 11/23 responses of measurable lesions occurring at doses ≥2000 mg/m2 as compared to 2/23 responses at a dose of 1500 mg/m2. The treatment regimen was able to be given on an outpatient basis with only routine supportive measures. High-dose etoposide may come to play a role in high-dose combination chemotherapy regimens for advanced breast cancer.

AB - High-dose etoposide (1500-2500 mg/m2) was used for the treatment of 23 previously treated patients with advanced breast cancer. Six of 23 (26%) showed objective regression with a median duration of response of 5 months. Responses were seen at all sites apart from bone. Response was related to dose level with 11/23 responses of measurable lesions occurring at doses ≥2000 mg/m2 as compared to 2/23 responses at a dose of 1500 mg/m2. The treatment regimen was able to be given on an outpatient basis with only routine supportive measures. High-dose etoposide may come to play a role in high-dose combination chemotherapy regimens for advanced breast cancer.

KW - Breast cancer

KW - Etoposide

KW - High-dose chemotherapy

UR - https://www.scopus.com/pages/publications/0026557923

U2 - 10.1159/000227021

DO - 10.1159/000227021

M3 - Article

C2 - 1574244

AN - SCOPUS:0026557923

SN - 0030-2414

VL - 49

SP - 104

EP - 107

JO - Oncology

JF - Oncology

IS - 2

ER -

High-dose etoposide in treatment of metastatic breast cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this